Hikal Limited

NSEI:HIKAL Stock Report

Market Cap: ₹48.4b

Hikal Valuation

Is HIKAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HIKAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HIKAL (₹393) is trading above our estimate of fair value (₹2.41)

Significantly Below Fair Value: HIKAL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HIKAL?

Key metric: As HIKAL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HIKAL. This is calculated by dividing HIKAL's market cap by their current earnings.
What is HIKAL's PE Ratio?
PE Ratio65.7x
Earnings₹736.02m
Market Cap₹48.36b

Price to Earnings Ratio vs Peers

How does HIKAL's PE Ratio compare to its peers?

The above table shows the PE ratio for HIKAL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.8x
JSLL Jeena Sikho Lifecare
56.6xn/a₹47.7b
AARTIPHARM Aarti Pharmalabs
25.2xn/a₹57.6b
509079 Gufic Biosciences
49.7xn/a₹42.2b
524348 Aarti Drugs
27.8x31.5%₹42.3b
HIKAL Hikal
65.7x49.2%₹48.4b

Price-To-Earnings vs Peers: HIKAL is expensive based on its Price-To-Earnings Ratio (65.7x) compared to the peer average (39.8x).

Price to Earnings Ratio vs Industry

How does HIKAL's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.79m
524652 Ind-Swift
2.1xn/aUS$13.52m
No more companies available in this PE range
HIKAL 65.7xIndustry Avg. 32.4xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HIKAL is expensive based on its Price-To-Earnings Ratio (65.7x) compared to the Indian Pharmaceuticals industry average (32.4x).

Price to Earnings Ratio vs Fair Ratio

What is HIKAL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HIKAL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio65.7x
Fair PE Ratio55.1x

Price-To-Earnings vs Fair Ratio: HIKAL is expensive based on its Price-To-Earnings Ratio (65.7x) compared to the estimated Fair Price-To-Earnings Ratio (55.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HIKAL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹393.00
₹435.00
+10.7%
3.4%₹450.00₹420.00n/a2
Nov ’25₹383.40
₹425.00
+10.9%
1.2%₹430.00₹420.00n/a2
Oct ’25₹372.05
₹425.00
+14.2%
1.2%₹430.00₹420.00n/a2
Sep ’25₹329.30
₹397.50
+20.7%
8.2%₹430.00₹365.00n/a2
Aug ’25₹338.50
₹347.50
+2.7%
5.0%₹365.00₹330.00n/a2
Jul ’25₹345.85
₹347.50
+0.5%
5.0%₹365.00₹330.00n/a2
Jun ’25₹284.85
₹347.50
+22.0%
5.0%₹365.00₹330.00n/a2
Dec ’24₹283.95
₹328.00
+15.5%
6.7%₹350.00₹306.00n/a2
Nov ’24₹280.35
₹353.00
+25.9%
13.3%₹400.00₹306.00₹383.402
Oct ’24₹295.40
₹353.00
+19.5%
13.3%₹400.00₹306.00₹372.052
Sep ’24₹308.45
₹353.00
+14.4%
13.3%₹400.00₹306.00₹329.302
Aug ’24₹290.90
₹353.00
+21.3%
13.3%₹400.00₹306.00₹338.502
Jul ’24₹313.45
₹353.00
+12.6%
13.3%₹400.00₹306.00₹345.852
Jun ’24₹310.40
₹353.00
+13.7%
13.3%₹400.00₹306.00₹284.852
May ’24₹295.50
₹387.50
+31.1%
3.2%₹400.00₹375.00₹303.602
Apr ’24₹281.65
₹387.50
+37.6%
3.2%₹400.00₹375.00₹275.502
Mar ’24₹300.40
₹387.50
+29.0%
3.2%₹400.00₹375.00₹278.852
Feb ’24₹350.90
₹350.00
-0.3%
5.7%₹370.00₹330.00₹296.852
Jan ’24₹410.10
₹332.67
-18.9%
8.9%₹370.00₹298.00₹300.203
Dec ’23₹339.60
₹332.67
-2.0%
8.9%₹370.00₹298.00₹283.953
Nov ’23₹331.25
₹321.00
-3.1%
11.9%₹375.00₹290.00₹280.353

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

7D

-4.9%

1Y

2.3%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

7D

9.2%

1Y

22.1%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹926.75

7D

-2.4%

1Y

18.8%